BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 33891901)

  • 1. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.
    Jevtić P; Haakonsen DL; Rapé M
    Cell Chem Biol; 2021 Jul; 28(7):1000-1013. PubMed ID: 33891901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
    Kozicka Z; Thomä NH
    Cell Chem Biol; 2021 Jul; 28(7):1032-1047. PubMed ID: 33930325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches.
    Scholes NS; Mayor-Ruiz C; Winter GE
    Cell Chem Biol; 2021 Jul; 28(7):1048-1060. PubMed ID: 33811812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
    Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands.
    Han B
    J Biol Chem; 2020 Nov; 295(45):15280-15291. PubMed ID: 32859748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.
    De Cesare V; Johnson C; Barlow V; Hastie J; Knebel A; Trost M
    Cell Chem Biol; 2018 Sep; 25(9):1117-1127.e4. PubMed ID: 30017913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
    Kannt A; Đikić I
    Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction.
    Simonetta KR; Taygerly J; Boyle K; Basham SE; Padovani C; Lou Y; Cummins TJ; Yung SL; von Soly SK; Kayser F; Kuriyan J; Rape M; Cardozo M; Gallop MA; Bence NF; Barsanti PA; Saha A
    Nat Commun; 2019 Mar; 10(1):1402. PubMed ID: 30926793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of ubiquitin ligases in the PROTAC drug design.
    Chen Y; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developments of CRBN-based PROTACs as potential therapeutic agents.
    Wang C; Zhang Y; Wu Y; Xing D
    Eur J Med Chem; 2021 Dec; 225():113749. PubMed ID: 34411892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Special Focus Issue - Targeted protein degradation: a new paradigm in medicinal chemistry.
    Wall H
    Future Med Chem; 2022 Jan; 14(3):115-117. PubMed ID: 35080920
    [No Abstract]   [Full Text] [Related]  

  • 20. Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation.
    Mou Y; Wen S; Gao X; Jiang ZY
    Future Med Chem; 2022 Jan; 14(3):139-141. PubMed ID: 34814705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.